HanAll Biopharma and Daewoong sign deal to develop Parkinson’s therapy
Pharmaceutical Technology
MAY 26, 2023
HanAll Biopharma and Daewoong Pharmaceutical will combine their resources and knowledge to develop NurrOn’s ATH-399A and other compounds targeting Nurr1 [nuclear receptor-related 1 protein] to treat neurodegenerative disorders. They will help to progress ATH-399A towards a Phase I trial.
Let's personalize your content